Conclusions
miRNA-145 is significantly altered in OSCC in our patient population and its reduced values carry a poor prognosis. Its interaction with CSCs may not be significant but mean miRNA-145 levels are lower in tumors with CSCs. There should be further studies on the larger sample size for these two biomarkers, to know its value.
Methods
In a prospective observational study 50 samples from patients of OSCC and 20 from unremarkable oral mucosa were studied. After initial detailed histology, miRNA-145 profiling was performed using qRT-PCR, followed by CD-133 immunohistochemistry (IHC).
Results
The mean age of patients with oral cancer was 47.5 ± 10.25 years. Mean miR-145 levels in OSCC were 0.4312 ± 0.32026 and mean in healthy controls was 0.99 ±0 .21771. There was significant downregulation of miRNA-145 in cases with respect to controls. Significant reduced levels of miRNA-145 with respect to higher clinical tumor size, pathological pT tumor, nodal status, and resultant clinical tumor stage was observed. As far as presence and absence of stem cells was concerned it was seen that tumors displaying presence of stem cells highlighted by CD-133 had lower levels of miRNA-145 as compared to tumors with absent CD-133 staining. Conclusions: miRNA-145 is significantly altered in OSCC in our patient population and its reduced values carry a poor prognosis. Its interaction with CSCs may not be significant but mean miRNA-145 levels are lower in tumors with CSCs. There should be further studies on the larger sample size for these two biomarkers, to know its value.